Treatmentexperimental

BPC-157 Peptide Therapy

A synthetic peptide fragment marketed by clinics for tissue repair, tendon/joint recovery, gut healing and reduced inflammation.

A synthetic peptide fragment marketed by clinics for tissue repair, tendon/joint recovery, gut healing and reduced inflammation. Sold as injectable, oral capsule or nasal formulations, often on a monthly-cycle basis.

Evidence

experimental

Evidence for recovery/longevity claims is almost entirely preclinical (rodent) with no adequate human RCTs, so the marketed human benefits remain unproven.

Regulatory notes

European Union
Not authorised as a medicine by the EMA or Spanish AEMPS; no legal marketed human product, so clinic sale sits outside approved-medicine channels.
United States
Not FDA-approved for any use; placed on the FDA 503A Category 2 list of bulk substances with significant safety risks ('do not compound') and referred to PCAC review.
United Arab Emirates
No DHA/DoH marketing authorisation; unapproved peptides are not permitted for prescription/import as licensed medicines.
United Kingdom
Not licensed by the MHRA for human use; only lawful within an unlicensed 'special' or research context, not as a general wellness product.

General information, not medical or legal advice. See our disclaimer.

Also known as

BPC157, BPC 157, Body Protection Compound 157, Bepecin, PL 14736, pentadecapeptide BPC 157

Where to find it

40 clinics in the directory offer bpc-157 peptide therapy. Prices shown are the cheapest for this treatment where published; always confirm with the venue.

Back to glossary